Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions

Core Insights - Altimmune, Inc. is presenting findings on pemvidutide, a novel GLP-1/glucagon dual receptor agonist, at the American Diabetes Association's 85 Scientific Sessions, focusing on its potential in treating metabolic dysfunction-associated steatohepatitis (MASH), obesity, alcohol use disorder (AUD), and alcohol-associated liver disease (ALD) [1][4]. Group 1: Presentation Details - The oral presentation titled "Effects of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids in Subjects with Obesity or Overweight" will be held on June 21, 2025, at 5:45 PM CDT [2]. - Three poster presentations will cover topics including cardiovascular safety, non-invasive tests of central adiposity, and cholesterol transport in a hamster model, all scheduled for June 22, 2025 [2]. Group 2: Pemvidutide Overview - Pemvidutide is designed to activate GLP-1 and glucagon receptors, mimicking the effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure [3]. - Clinical trials have shown that pemvidutide leads to significant weight loss, preservation of lean mass, and reductions in triglycerides, LDL cholesterol, liver fat content, and blood pressure [4]. Group 3: Regulatory Status and Trials - The U.S. FDA has granted Fast Track designation to pemvidutide for MASH treatment, with the MOMENTUM Phase 2 obesity trial completed in 2024 and ongoing IMPACT Phase 2b MASH trial expected to report top line results in Q2 2025 [4]. - IND applications for AUD and ALD have received FDA clearance, with the Phase 2 trial for AUD starting in Q2 2025 and the ALD trial set to begin in Q3 2025 [4]. Group 4: Company Background - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases, with pemvidutide as its lead program [5].